ABL Kinase Domain Mutation
Test Code
Clinical Significance
ABL Kinase Domain Mutation - Kinase inhibitors such as IMATINIB mesylate (ST1571;GLEEVEC) are effective in the treatment of chronic Myelogenous Leukemia (CML) by selectively inhibiting BCR-ABL fusion protein. Most patients in chronic phase maintain durable responses; however, many in blast crisis fail to respond, or relapse quickly. ABL kinase domain mutations are the most identified mechanism associated with relapse. The molecular monitoring in the first few months of therapy may play a crucial role in detecting patients at high risk of resistance to therapy. The ABL kinase mutation assay sequences exons 4-9 of ABL1 kinase ...
Test Resources
Test Details
Methodology
Reference Range(s)
Alternative Name(s)
Preferred Specimen(s)
5 mL whole blood or 3 mL bone marrow aspirate collected in an EDTA (lavender-top) tube
Alternative Specimen(s)
Whole blood collected in: Sodium heparin (green-top) tube or ACD solution B (yellow-top) tube • Bone marrow aspirate collected in: Sodium heparin (green-top) tube
Minimum Volume
3 mL whole blood • 1 mL bone marrow
Collection Instructions
After collection of the sample, draw date and time, as well as sample type, must be written on the tube and included as requested information. Ship sample immediately due to short sample stability of 72 hours.
If the stability of the sample cannot be determined, delay in result or cancellation of test may occur.
Do not reject specimens, send to laboratory for screening.
Transport Container
EDTA (lavender-top) tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 72 hours
- Refrigerated: 72 hours
- Frozen: Unacceptable
Setup Schedule
If the stability of the sample cannot be determined, delay in result or cancellation of test may occur.
Do not reject specimens, send to laboratory for screening.
Refrigerated: 72 hours
Frozen: Unacceptable